glp-1 autoimmune disease The Beneficial Effects of Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties GLP1 microdosing for autoimmune conditions?
Description
Your patient, who has had T2DM for several years, wants to know why the GLP-1 therapy isnt working as fast as it should for him
Qsymia, approved in 2012, combines an old stimulant, phentermine, with topiramate, an anticonvulsant medication
2017;5:e13102
References 2018 The Author(s)
Furthermore, despite GLP-1RAs have consistently contributed to the improvement of PsO severity and systemic inflammation, disentangling metabolic-driven benefits from direct immunomodulatory effects is still a challenge
